Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rani Therapeutics (Nasdaq: RANI) disclosed an inducement stock option grant to new Chief Financial Officer Nicholas Maestas under Nasdaq Listing Rule 5635(c)(4).

Rhea-AI Summary

Rani Therapeutics (Nasdaq: RANI) disclosed an inducement stock option grant to new Chief Financial Officer Nicholas Maestas under Nasdaq Listing Rule 5635(c)(4). The option covers 2,000,000 shares of Class A common stock, granted on July 17, 2026, with an exercise price of $0.6973 per share, equal to the closing price on the grant date.

The option has a ten-year term and vests over four years: 25% on the one-year anniversary of employment commencement and the remainder in equal monthly installments over the following 36 months, subject to continued service. The grant was approved by the Board’s Compensation Committee under Rani’s 2026 Equity Inducement Plan.

Positive

• None.

Negative

• Potential dilution from up to 2,000,000 new shares if options are exercised

Argus Jul 21 session 4 alerts

+0.68% close to close 0.8x rel. volume Open Argus

Details

News Market Reaction – RANI

+13.4% Peak Tracked

-4.2% Trough Tracked

$78.37M Market Cap

In the Jul 21 session, RANI gained 0.68%, reflecting a mild positive market reaction. Argus tracked a peak move of +13.4% during that session. Argus tracked a trough of -4.2% from its starting point during tracking. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

Historical event 1075624 provides a recent CFO-related reference for this compensation announcement....

Analysis

Historical event 1075624 provides a recent CFO-related reference for this compensation announcement. The active S-3 is a resale registration, while low short positioning remains a separately sourced risk context.

Key Figures

Option shares: 2,000,000 shares Grant date: July 17, 2026 Exercise price: $0.6973 per share +5 more

Option shares

2,000,000 shares

CFO inducement award

Grant date

July 17, 2026

Stock option grant

Exercise price

$0.6973 per share

Equal to closing price on grant date

Option term

Ten years

Stock option

Vesting period

Four years

Stock option

Initial vesting

25%

Shares vest on one-year employment anniversary

Initial vesting date

One-year anniversary

Commencement of employment

Remaining vesting

36 months

Equal installments after initial vesting

Historical Context

5 past events · Latest: Jul 15

5 events

1. Jul 15

   Phase 1a data

   24h Move

   +4.3%

   Phase 1a oral RT-114 data showed bioavailability above matched subcutaneous dosing.

2. Jul 09

   R&D collaboration

   24h Move

   -1.6%

   R&D collaboration with PegBio expanded oral delivery exploration across obesity candidates.

3. Jun 29

   CFO appointment

   24h Move

   +3.9%

   Nicholas Maestas appointed CFO, bringing reported biotech finance and strategy experience.

4. May 26

   Registered offering

   24h Move

   -12.1%

   Registered direct offering priced at-the-market for about $20.0 million gross proceeds.

5. May 15

   Quarterly results

   24h Move

   -10.0%

   First-quarter results included $43.4 million liquidity and a planned CFO transition.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

nasdaq listing rule 5635(c)(4), bioavailability, subcutaneous injection

3 terms

nasdaq listing rule 5635(c)(4) regulatory

"approved by the Compensation Committee ... in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

bioavailability medical

"clinical studies to evaluate safety, tolerability and bioavailability"

Bioavailability is the measure of how much and how quickly a substance, such as a medication or nutrient, enters the bloodstream and becomes available for use by the body. For investors, it matters because it influences how effectively a product works and how quickly results are seen, which can impact a company's success and the potential value of related investments. Think of it like how much of a medicine actually reaches your bloodstream after taking it—that determines how well it can do its job.

subcutaneous injection medical

"replace subcutaneous injection or intravenous infusion"

A subcutaneous injection is a method of delivering a medicine or vaccine by inserting a small needle just under the skin into the thin layer of fat beneath the outer skin. For investors, administration by subcutaneous injection matters because it influences patient convenience, dosing frequency, manufacturing complexity and distribution costs, all of which affect how widely a treatment is adopted and how it is priced—like choosing a product that customers can easily use at home versus one that needs a clinic visit.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN JOSE, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics”; “Rani” or the “Company”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today reported that it granted an equity award in the form of a stock option to purchase 2,000,000 shares of Rani Class A common stock to Nicholas Maestas, Rani’s new Chief Financial Officer, as an inducement material to his acceptance of employment with Rani.

The stock option was granted on July 17, 2026. The stock option has an exercise price of $0.6973 per share, which is equal to the closing price of Rani’s Class A common stock on the grant date, has a ten-year term and vests over four years, with 25% of the shares underlying the option vesting on the one-year anniversary of commencement of his employment and the remaining shares vesting over the following 36 months in equal installments of whole shares, subject to continued service with Rani through the applicable vesting dates.

The stock option grant was approved by the Compensation Committee of Rani’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and is subject to the terms and conditions of Rani’s 2026 Equity Inducement Plan and the form of stock option agreement under that plan.

About Rani Therapeutics

Rani Therapeutics is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. Rani has developed the RaniPill^® capsule, a novel, proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using RaniPill^® capsule technology.

Investor Contact:
investors@ranitherapeutics.com
Media Contact:
media@ranitherapeutics.com

FAQ

What inducement stock option did Rani Therapeutics (Nasdaq: RANI) grant its new CFO in July 2026?

Rani Therapeutics granted its new CFO a stock option for 2,000,000 Class A shares. According to Rani Therapeutics, the option was granted on July 17, 2026, as an inducement award in connection with his employment and is issued under the 2026 Equity Inducement Plan.

What is the exercise price of the July 2026 Rani Therapeutics (RANI) CFO inducement option?

The exercise price is $0.6973 per share for the inducement stock option. According to Rani Therapeutics, this price equals the closing price of its Class A common stock on the July 17, 2026 grant date, consistent with typical equity compensation practices.

How does the Rani Therapeutics (RANI) CFO inducement stock option vest?

The option vests over four years. According to Rani Therapeutics, 25% of the 2,000,000 shares vest on the one-year anniversary of employment commencement, with the remaining shares vesting in equal monthly installments over the following 36 months, subject to continued service.

What is the term of the Rani Therapeutics (RANI) CFO inducement stock option granted in July 2026?

The inducement stock option has a ten-year term. According to Rani Therapeutics, the option was granted on July 17, 2026, and remains exercisable for ten years, subject to its vesting schedule, plan terms, and the CFO’s continued service with the company.

Under which plan and rules was the Rani Therapeutics (RANI) July 2026 inducement option granted?

The option was granted under the 2026 Equity Inducement Plan in line with Nasdaq Rule 5635(c)(4). According to Rani Therapeutics, the Compensation Committee of the Board approved the grant, and it is subject to the plan and related stock option agreement terms.